We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Varinder
Athwal
varinder.athwal@manchester.ac.uk
Dr
Varinder
Athwal
varinder.athwal@manchester.ac.uk
Diseases of liver
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Liver disease is a silent epidemic. Four in ten people in the North West are likely to have evidence of liver disease. A small but significant proportion of these patients develop scarring, leading to end-stage cirrhosis. All too frequently this is detected in very advanced stages, where treatment cannot reverse the condition. It is one of the UK's largest health challenges. At present we use a wide range of single tests that individually struggle to identify disease and high-risk patients early.
We are implementing a new pathway for the assessment of patients with abnormal liver blood tests or high risk for liver disease (please see pathway in protocol). This novel pathway will allow assessment of patients in Community Liver Assessment Clinics (CLAC) with the expectation that only 20% of patients assessed would need to be seen in secondary care for further assessment. We expect, to be assessing, 750 patients per year in this pathway. This pathway will bring together a large group of patients with liver disease. As part of the clinical assessment we will be undertaking investigations to diagnose disease and assess extent. This will generate significant information, that we currently use in isolation to make the aforementioned assessments. In this study, we would like to bring together all this data into a curated database. To this end, we would offer all patients who attend the CLAC for clinical need to enrol into the study so we can cohort their data. We would generate a database to combine all data, alongside some other, non-invasive tests, done alongside routine clinical tests.
Our project will address this lack of answers by teaming up with innovative companies to make software that joins together a wide range of different tests to make an algorithm to detect disease earlier.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
The below patients will not be eligible for the community liver clinic and hence excluded from the study: • Age < 18 years. • Pregnancy/breast-feeding. Women of childbearing potential (not > 2 years post- menopausal and/or not surgically sterilised) must have a negative blood serum pregnancy test. • Isolated biulirubinaemia. • Known pre-existing liver disease. • Acutely unwell. • Suspected malignancy.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Varinder
Athwal
varinder.athwal@manchester.ac.uk
Dr
Varinder
Athwal
varinder.athwal@manchester.ac.uk
The study is sponsored by MANCHESTER UNIVERSITY NHS FOUNDATION TRUST and funded by Innovate UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 45696
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
